Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Milestone Wins NMPA Approval For Etripamil Nasal Spray In PSVT

3 September 2026 · By · Wire by Fusion42

Published

3 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at rttnews.com →

◆ Verified

Fusion42 · 4 September 2026 · Fusion42 review

Milestone Pharmaceuticals has received approval from China's National Medical Products Administration (NMPA) for its Etripamil nasal spray, intended for the treatment of paroxysmal supraventricular tachycardia (PSVT). This marks a significant regulatory milestone enabling Milestone to commercialise the drug in the Chinese market.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You now have a credible entry into China's cardiology drug market as Milestone’s regulatory approval clears key barriers. Competitors selling PSVT solutions should watch for market share shifts as patient access to nasal Etripamil increases.

◆ Coverage

1 source · 3 Sep 2026

◆ Related on Wire

◆ Topics

Biotechdrug-approvalnmpapsvtnasal-spraymilestone-pharmachina